BioSpace News Archive

Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 411,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.

Skanska has signed an additional contract with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.

XVIVO Perfusion AB In 2014, XVIVO introduced an innovative liver technology to the Italian market, designed for oxygenated perfusion prior to transplantation.

Zealand Pharma A/S announced the submission of a New Drug Application to the US Food and Drug Administration for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome dependent on parenteral support.

BeiGene, Ltd. today announced the U.S. Food and Drug Administration (FDA) has approved a label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA® (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).

Senti Biosciences, Inc. today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202.

AlloVir, Inc. today provided an update on its three Phase 3 clinical trials with posoleucel.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments.